Navigation Links
Boston Strategic Partners, Inc. is Utilizing Electronic Health Record Data to Analyze Hospital Treated Pneumonia
Date:9/14/2017

Boston Strategic Partners, Inc. (BSP), a life-sciences and healthcare consulting firm is utilizing its extensive experience with Health Economics and Outcomes Research (HEOR) and ‘big data’ to provide in-depth analysis of pneumonia patients characteristics, medication management, costs and laboratory testing. In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. BSP has access to real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals and health systems across the US, representing nearly 16% of the US population.

30% of all hospital discharges involve treatment of infectious organisms. Pneumonia is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of sepsis patient characteristics, medication management, costs, and laboratory testing.

Gram-negative bacteria are the likely causative agents of most pneumonia infections and physicians treat most of these patients with levofloxacin, ceftriaxone, and azithromycin. From 2010-2015, drug resistant organisms caused a surprising 20% of bacterial pneumonia infections. After confirmatory diagnosis, over half of sepsis patients undergo a change in antibiotic therapy.
BSP provides quantitative, objective data using real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antibiotic resistant pathogens and antimicrobial stewardship.

Areas of focus:

  •     Acute Myocardial Infarction
  •     Antibiotic resistance
  •     Chronic Kidney Disease (CKD)
  •     Chronic Obstructive Pulmonary Disease (COPD)
  •     Extrinsic Asthma
  •     Hip and knee surgery
  •     Hypertension
  •     Influenza (and resulting complications)
  •     Obesity
  •     Osteoarthritis
  •     Schizophrenia
  •     Stroke
  •     Type 2 Diabetes (and resulting complications)

For more information about Boston Strategic Partners, Inc. and our data analysis reports visit: http://www.bostonsp.com/reports.

About BSP
Founded in 2003, Boston Strategic Partners, Inc. is a dedicated healthcare and life sciences company. We offer five different types of services:

  •     Business & Clinical Strategy
  •     Health Economics & Outcomes Research (HEOR)
  •     Medical Communications
  •     Regulatory Strategy
  •     Financial Advisory

For more information or to schedule a meeting with our team, please email us at info(at)bostonsp(dot)com

Read the full story at http://www.prweb.com/releases/2017/09/prweb14690268.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. PRC Clinical Partners With SDC to Expand ClinPulse Event Series to the Boston Biotech Hub
2. Boston Strategic Partners, Inc. is utilizing Electronic Health Record Data for real world data analysis
3. 4 Strategic Takeaways from Open Data Science Conference 2017 in Boston
4. Stratevi Expands to East Coast with Boston Office Opening
5. Brainstorm Cell Therapeutics to Present at ARMs 5th Annual Cell & Gene Therapy Investor Day, April 27 in Boston
6. DrugDev Joins Boston’s Technology Trendsetters to Host MassTLC’s NewCo Festival in Boston
7. Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017
8. Boston Biomedical Celebrates 10-Year Anniversary of its Founding and Announces Appointment of Patricia S. Andrews as Chief Executive Officer
9. At 6th Annual Clinical Trial Supply New England 2017 Conference in Boston Asymmetrex Introduces A First Specific Quality Control Test for Therapeutic Tissue Stem Cells
10. Asymmetrex’s Head Will Lead Discussion on Supplying Private Stem Cell Clinics at the 6th Annual Clinical Trial Supply New England 2017 Conference in Boston
11. Boston Children’s Hospital and uBiome to Investigate Premature Births
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer and recently ... have entered into a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. ... for gene editing across all applications. , Under the terms of the agreement, ...
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded coverage ... its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats ... sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates the ...
(Date:10/12/2017)... , ... October 12, 2017 ... ... has launched Rosalind™, the first-ever genomics analysis platform specifically designed for life ... Named in honor of pioneering researcher Rosalind Franklin, who made a major ...
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
Breaking Biology Technology:
(Date:8/23/2017)... general public,s help is being enlisted in what,s thought to be the ... the human body –and are believed to affect health.  ... The Microbiome Immunity Project is the largest study to ... The project's goal is to help advance scientific knowledge of the role ... The ...
(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
Breaking Biology News(10 mins):